Back to search

Article

Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent Tumors

2024-06-28

Abstract excerpt

<h4>SUMMARY</h4> Current chemotherapies provide limited clinical benefits to patients with pancreatic ductal adenocarcinoma (PDAC), partly due to the lack of effective biomarkers for personalized therapy. KRAS activating mutations occur in almost 90% of PDAC cases, leading to a subset of tumors d ependent on KRAS for survival (dKRAS). Assessing dKRAS in PDAC can be achieved using gene expression signature score...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8eb44454-69ac-524b-b1e6-0f6aa78972c0
DOI
10.1101/2024.06.23.599676
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent TumorsDOI 10.1101/2024.06.23.599676
DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.Semantic proximity
Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA VariantsSemantic proximity
Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC.Semantic proximity
Targeting DNA Damage Repair Mechanisms in Pancreas CancerSemantic proximity
Targeted Therapies in Pancreatic Cancer: A New Era of Precision MedicineSemantic proximity
DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparibSemantic proximity
Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.Semantic proximity
Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP InhibitionSemantic proximity
Recent advances in precision medicine for pancreatic ductal adenocarcinomaSemantic proximity
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectivesSemantic proximity
The role of PARP inhibitors in BRCA mutated pancreatic cancerSemantic proximity
DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical PerspectivesSemantic proximity
Select a neighboring publication to make it the new centre.